Cracking The Code: Understanding Analyst Reviews For Stryker - Stryker (NYSE:SYK)

Ratings for Stryker (NYSE:SYK) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

	Bullish	Somewhat Bullish	Indifferent
Total Ratings	5	11	3
Last 30D	0	1	0
1M Ago	0	0	0
2M Ago	5	7	3
3M Ago	0	3	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $398.89, a high estimate of $445.00, and a low estimate of $370.00. Marking an increase of 5.68%, the current average surpasses the previous average price target of $377.44.

Investigating Analyst Ratings: An Elaborate Study

The perception of Stryker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Drew Ranieri	Morgan Stanley	Raises	Overweight	$445.00	$370.00
Joanne Wuensch	Citigroup	Raises	Buy	$411.00	$406.00
Matt Miksic	Barclays	Raises	Overweight	$418.00	$402.00
Ryan Zimmerman	BTIG	Raises	Buy	$394.00	$383.00
Kyle Rose	Canaccord Genuity	Raises	Buy	$400.00	$360.00
Shagun Singh	RBC Capital	Raises	Outperform	$400.00	$386.00
Matt O'Brien	Piper Sandler	Raises	Overweight	$420.00	$380.00
Robbie Marcus	JP Morgan	Raises	Overweight	$420.00	$375.00
Richard Newitter	Truist Securities	Raises	Hold	$380.00	$370.00
Vijay Kumar	Evercore ISI Group	Raises	Outperform	$384.00	$380.00
Larry Biegelsen	Wells Fargo	Raises	Overweight	$405.00	$381.00
Danielle Antalffy	UBS	Raises	Neutral	$370.00	$366.00
Jeff Johnson	Baird	Raises	Outperform	$405.00	$378.00
Mike Matson	Needham	Raises	Buy	$409.00	$393.00
Ryan Zimmerman	BTIG	Raises	Buy	$383.00	$374.00
Richard Newitter	Truist Securities	Raises	Hold	$370.00	$345.00
Vijay Kumar	Evercore ISI Group	Raises	Outperform	$380.00	$365.00
Matt O'Brien	Piper Sandler	Maintains	Overweight	$380.00	$380.00
Mike Polark	Wolfe Research	Announces	Outperform	$405.00	-

Key Insights:

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stryker. This offers insight into analysts' perspectives on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.
Price Targets: Understanding forecasts, analysts offer estimates for Stryker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Stryker analyst ratings.

About Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

A Deep Dive into Stryker's Financials

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Stryker's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Stryker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 15.18%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.18%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Stryker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.01%, the company may face hurdles in achieving optimal financial performance.

Debt Management: With a high debt-to-equity ratio of 0.77, Stryker faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Core of Analyst Ratings: What Every Investor Should Know

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

SYKStryker Corp

$292.000.39%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.